{"organizations": [], "uuid": "cc8c710f9eaf1f8cfe6df960c4e67343c529d547", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180404.html", "section_title": "Archive News &amp; Video for Wednesday, 04 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-thrombogenics-reports-initial-data/brief-thrombogenics-reports-initial-data-from-thr-317-clinical-study-idUSFWN1RG0Z4", "country": "US", "domain_rank": 408, "title": "BRIEF-Thrombogenics Reports Initial Data From THR-317 Clinical Study", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.152, "site_type": "news", "published": "2018-04-04T13:36:00.000+03:00", "replies_count": 0, "uuid": "cc8c710f9eaf1f8cfe6df960c4e67343c529d547"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-thrombogenics-reports-initial-data/brief-thrombogenics-reports-initial-data-from-thr-317-clinical-study-idUSFWN1RG0Z4", "ord_in_thread": 0, "title": "BRIEF-Thrombogenics Reports Initial Data From THR-317 Clinical Study", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 4 (Reuters) - THROMBOGENICS NV:\n* CLINICAL TRIAL IS TARGETED TO BE INITIATED IN Q2 2018 * ‍STUDY ENROLLED A TOTAL OF 49 PATIENTS, INCLUDED ANTI-VEGF NAÏVE PATIENTS AND AS SUB-OPTIMAL ANTI-VEGF RESPONDERS​\n* ‍THR-317 WAS SAFE AND WELL TOLERATED​\n* ‍NO DOSE-LIMITING TOXICITIES OR RELEVANT SAFETY EVENTS WERE REPORTED AT ANY DOSE LEVEL​\n* ‍DATA SUPPORT INITIATION OF A NEXT STUDY EVALUATING THR-317 IN COMBINATION WITH AN ANTI- VEGF​\n* ‍30% ANTI-VEGF TREATMENT NAÏVE 8MG GROUP SUBJECTS SHOWED A > OR EQUAL TO 15 LETTER GAIN FROM BASELINE\n* 5.3% ANTI-VEGF TREATMENT NAÏVE 4MG GROUP SUBJECTS SHOWED A > OR EQUAL TO 15 LETTER GAIN FROM BASELINE Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-04T13:36:00.000+03:00", "crawled": "2018-04-05T17:18:47.000+03:00", "highlightTitle": ""}